Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) was off $0.14 to $4.47 last week after the European Commission approved an MAA for Adasuve Staccato to treat mild to moderate agitation in adults with schizophrenia or bipolar disorder. Alexza's European commercialization partner Grupo Ferrer Internacional S.A. plans to launch the product in 3Q13.
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) jumped $1.18 (154%) to $1.94 on Wednesday after saying it will resubmit in late 2Q13 an NDA for Northera droxidopa to treat symptomatic neurogenic orthostatic hypotension (NOH). According to the company, FDA said data from Chelsea's Phase III Study 306B trial may be sufficient as the basis of the resubmission. Previously, the company said the agency had recommended an additional trial...